Ironwood puts GERD hopeful on the chopping block, along with 100 staffers after flop

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations, failing a phase 3 program and thrown out onto the garbage pile.

Things looked shaky three years ago when the drug, then in midstage testing, met its primary endpoint, but not by much, and investors questioned the drug’s future.